Search

News MS in the Digital Age: Doctor as a Lifebuoy in the Sea of Information

How to offer a helping hand to patients amidst the flood of information and why is communication perhaps more important than ever? And what should the standards in the doctor-patient relationship with multiple sclerosis be? This unusual topic was explored in a publication in the journal Neurosciences.

Source: Multiple Sclerosis 15. 8. 2023

News Chairwoman of Revma Liga ČR: I Hope We Improve Our Approach and Treatment of Osteoporosis in the Czech Republic

Patients with inflammatory rheumatic diseases have a significantly increased risk of developing osteoporosis and related fractures. At the same time, this disease is considerably underestimated in the Czech Republic, and more attention is given to it only at the stage of osteoporotic fractures. To what extent does the patient organization Revma Liga ČR, which unites patients with rheumatic diseases, engage in this issue? We asked its chairwoman Edita Müllerová.

Source: Osteoporosis – Trends in Sequential Therapy 20. 12. 2023

News Dabigatran Etexilate in the Treatment of Acute Thromboembolic Disease in Children

Until now, standard anticoagulants such as low-molecular-weight heparin or unfractionated heparin and others have been used in pediatric patients for the treatment of thromboembolism. The study presented below aimed to determine whether dabigatran could be the drug of the future in the treatment of pediatric patients with thromboembolism.

Source: Anticoagulant Treatment 22. 7. 2021

News Safety and Effectiveness of Lurasidone in Adolescents with Schizophrenia

An open-label extension of a placebo-controlled study involving 271 patients aged 13–17 years with schizophrenia showed minimal impact on body weight, lipid levels, prolactin, and blood glucose during 2 years of treatment while maintaining and deepening the alleviation of schizophrenia symptoms.

Source: Modern Treatment of Schizophrenia 18. 5. 2021

News Targeted Therapy for DLBCL Patients Who Cannot Undergo Bone Marrow Transplant

An international team of hemato-oncologists has been involved in testing polatuzumab vedotin in patients with diffuse large B-cell lymphoma (DLBCL) who have an unfavorable prognosis. In an article published at the beginning of 2020 in the Journal of Clinical Oncology, they analyze data collected in the early phases of clinical evaluation.

Source: Non-Hodgkin Lymphomas and CLL 11. 5. 2020

News The Importance of Early Diagnosis and Treatment of AATD in Preventing Pulmonary Emphysema

Alpha-1 antitrypsin deficiency (AATD) is a risk factor for the development of various diseases, including pulmonary emphysema. Currently, it is significantly underdiagnosed, and the availability of effective treatment is a reason for conducting its screening. The Czech Pneumological and Phthisiological Society ČLS JEP (ČPFS) recommends examining AAT levels in all patients with irreversible obstructive ventilatory disorders of any origin, direct relatives of patients with AATD, and individuals with chronic liver disease of unclear origin. The RAPID-OLE study has shown that treatment of alpha-1 antitrypsin deficiency modifies the course of this disease and underscores the importance of early intervention.

Source: Deficiency of Alpha-1-Antitrypsin 13. 7. 2020

News Experience from Clinical Practice with Intestinal Gel LECIG in Treating Parkinson's Disease

A Swedish observational study evaluated the applicability of the LECIG intestinal gel, which contains levodopa (20 mg/ml), carbidopa (5 mg/ml), and entacapone (20 mg/ml), in clinical practice for patients with Parkinson's disease.

Source: Parkinson's Disease 12. 5. 2022

Články časopisu Dysplasia and cervical cancer: current diagnostic possibilities

Author of the article: L. Rotter, P. Rotterová, I. Kinkorová Luňáčková, J. Kašpírková, M. Michal, R. Hudeček Source: Česká gynekologie | 4/2014 1. 8. 2014

Články časopisu Iron metabolism and its regulations

Author of the article: D. Vyoral, J. Petrák Source: Vnitřní lékařství | Suppl 2/2012 17. 8. 2012

News Biosimilar Bevacizumab in Patients with Non-Small Cell Lung Cancer

Biosimilar drugs are essentially analogous to generics for biological medicines. The patent protection for the original bevacizumab product will expire in the European Union in 2022. Consequently, several companies have already embarked on developing a biosimilar molecule.

Source: Oncological Treatment 15. 9. 2021

Články časopisu Hodgkin´s Lymhoma –⁠ the Treatment Aproaches Development and Current Trends

Author of the article: J. Kořen, M. Trněný Source: Klinická onkologie | Supplementum 3/2015 19. 10. 2015

News Current Treatment Options for Refractory/Relapsed CLL

How have treatment protocols for chronic lymphocytic leukemia changed in recent years? A review published in Acta Haematologica discusses the current therapeutic options for relapsed or refractory disease.

Source: Chronic Lymphocytic Leukemia 8. 9. 2022

News Results of Levothyroxine Treatment in Pregnant Women with Recurrent Pregnancy Losses with Subclinical Hypothyroidism or Anti-TPO Antibody Positivity

A recent meta-analysis of 15 studies involving a total of 1911 women with a history of recurrent pregnancy losses and positivity for thyroid peroxidase antibodies (TPOAb) or subclinical hypothyroidism showed the benefits of administering levothyroxine on pregnancy outcomes. Women with TPOAb experienced reductions in preterm births, miscarriages, premature rupture of membranes, and fetal growth retardation. Women with subclinical hypothyroidism saw an increase in live births and a decrease in miscarriages.

Source: Thyroid Disorders 16. 10. 2023

News Increase in Thyroid Cancer Incidence Due to the Coronavirus Pandemic?

According to available data, COVID-19 disease does not worsen the course of thyroid cancer. However, the restriction of medical care during the pandemic is associated with concern about an increase in the incidence of this malignant disease and the associated morbidity and mortality.

Source: Thyroid Disorders 6. 5. 2021

News To Vaccinate or Not to Vaccinate? That’s the Question for MS and COVID-19

What is the response of patients with multiple sclerosis (MS) to vaccination against COVID-19 considering the type of their treatment? Is there an increased risk of relapse after vaccination? And how to proceed with a particular patient? Although COVID-19 has been a relevant issue for a relatively long time, unfortunately, this topic remains current. Unlike in 2020, however, our knowledge has significantly advanced. Currently, relatively extensive data are available even for specific groups of the population –⁠ including precisely MS patients.

Source: Multiple Sclerosis 10. 10. 2022